Avian influenza is an infection caused by avian (bird) influenza (flu) viruses. These influenza viruses occur naturally among birds. Wild birds worldwide carry the viruses in their intestines, but usually do not get sick from them. However, avian influenza is very contagious among birds and can make some domesticated birds, including chickens, ducks, and turkeys, very sick and kill them.
Ducks and gulls are the natural hosts of influenza A virus. Ragnhild Tønnessen's PhD research project has characterised influenza A viruses in gulls and ducks in Norway. Her discoveries may lead to a better understanding of the epidemiology and host adaptation of influenza A virus.
A new study has found that a novel avian-origin H7N9 influenza A virus, which has recently emerged in humans, attaches moderately or abundantly to the epithelium of both the upper and lower respiratory tracts.
EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, and the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health announced a new strategy to identify the total number of wildlife viruses that could potentially cause emerging disease outbreaks that threaten both public and wildlife health.
Predisposition to cancer and other diseases, genetic testing, infectious proteins and ubiquitin signalling -- these are some of the topics internationally renowned speakers will tackle at The EMBO Meeting 2013 to be held in Amsterdam, the Netherlands, from 21-24 September 2013.
The emergence of a novel H7N9 avian influenza virus in humans in China has raised questions about its pandemic potential as well as that of related influenza viruses.
The H7N9 avian flu strain that emerged in China earlier this year has subsided for now, but it would be a mistake to be reassured by this apparent lull in infections. The virus has several highly unusual traits that paint a disquieting picture of a pathogen that may yet lead to a pandemic, according to lead scientists from the National Institute of Allergy and Infectious Diseases.
H7N9 pneumonia is characterized by imaging findings that differentiate it from other types of pneumonia, including rapidly progressive changes in the lungs and pulmonary connective tissues, according to the first study to describe radiologic findings in the disease. The results are published online in the journal Radiology.
Two symposia focusing on the ecological dynamics of infectious diseases such as avian influenza, Yellow Fever, and Lyme will take place during the Ecological Society of America's 98th Annual Meeting, held this year in Minneapolis, Minnesota.
Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced it has received clearance by Health Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine").
In an effort to sort out why some viruses such as influenza, Ebola and West Nile are so lethal, a team of U.S. researchers plans a comprehensive effort to model how humans respond to these viral pathogens.
Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine").
A known difficulty in fighting influenza (flu) is the ability of the flu viruses to mutate and thus evade various medications that were previously found to be effective. Researchers at the Hebrew University of Jerusalem have shown recently that another, more promising, approach is to focus on improving drugs that boost the body's natural flu killer system.
A new computer model could help scientists predict when a particular strain of avian influenza might become infectious from bird to human, according to a report to be published in the International Journal Data Mining and Bioinformatics.
A novel avian-origin reassortant influenza A (H7N9) virus emerged in China in February 2013, and is associated with severe lower respiratory tract diseases. To date, more than 100 human cases of infection, including at least 20 deaths, have been reported in China.
There has been a flurry of recent attention over two novel infectious agents: the first, a strain of avian influenza virus (H7N9) in China that is causing severe respiratory disease and other serious health complications in people; the second, a coronavirus, first reported last year in the Middle East, that has brought a crop of new infections.
Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is responsible for the current influenza outbreak in China.
A map of avian influenza (H7N9) risk is presented in Biomed Central's open access journal Infectious Diseases of Poverty today. The map is comprised of bird migration patterns, and adding in estimations of poultry production and consumption, which are used to infer future risk and to advise on ways to prevent infection.
The tick-borne Lone Star virus has been conclusively identified as part of a family of other tick-borne viruses called bunyaviruses, which often cause fever, respiratory problems and bleeding, according to new research led by scientists at UC San Francisco.
"China on Saturday reported its first case of H7N9 bird flu in the southern province of Hunan, the latest sign the virus that has killed 23 people in the country is continuing to spread," Reuters reports (Ruwitch, 4/29).
The journal Nature published an editorial and opinion piece on the emergence of the H7N9 avian influenza strain.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.